BCR‑ABL is a well‐characterized fusion oncoprotein resulting from a chromosomal translocation that has significant diagnostic, prognostic, and therapeutic relevance in hematologic malignancies.
– It promotes uncontrolled cell proliferation, inhibits apoptosis, and contributes to genomic instability.
– Quantitative measurement of BCR‑ABL transcript levels is used to monitor minimal residual disease (MRD) and predict response to therapy.
– BCR‑ABL is not only a diagnostic hallmark of CML and certain ALL cases but also a critical driver of disease progression that can be effectively targeted by molecular therapies.
(Will delete Record if Target field = "Delete") Home